Figure 2.
Anti-GD2 CAR T cells are promising approach to treat DIPG. Anti-GD2 CAR T cells could infiltrate into glioma tissues, and eliminate almost completely GD2-expressing cells after systemic injection (A). In contrast, anti-GD2 mAbs are hard to access glioma cells by crossing the blood brain barrier (B). This may be also the case in anti-immune check-point antibodies. DIPG, diffuse intrinsic pontine glioma.